Below are articles from various sources about members of MCB and their research.
The Fall 2014 edition of the MCB Transcript newsletter is now available, including research profiles of the following new faculty members: Nicholas Ingolia, Gloria Brar, Elçin Ünap, Dirk Hockemeyer, and Roberto Zoncu.
Surprising research on the role of cytoskeletal integrity in preventing protein misfolding from heat shock by Howard Hughes Investigator, Thomas and Stacey Siebel Distinguished Chair in Stem Cell Biology, and Professor of Genetics, Genomics and Development Andrew Dillin is in the Oct. 17 issue of the journal Science and is the focus of a NewsCenter article. The accumulation of improperly folded proteins has been linked to diseases such as Alzheimer’s, Parkinson’s, and Huntington’s.
Howard Hughes Investigator and Thomas and Stacey Siebel Distinguished Chair in Stem Cell Biology and Professor of Genetics, Genomics and Development Andrew Dillin, together with Nobelist Stan Prusiner from UCSF, will lead a new integrated center for research on neurodegenerative diseases. The center will be funded by $3 million from the Glenn Foundation for Medical Research and will pave the way for novel treatments for diseases linked to misfolded proteins and/or prions.
Professor Mary Claire King is the 2014 recipient of the prestigious Lasker~Koshland Award for Special Achievement in Medical Science for her work discovering the BRCA1 breast-cancer gene. King made her discovery while she was a faculty member at UC Berkeley in the School of Public Health and in the Department of Molecular & Cell Biology.
Director of QB3 and Eveland Warren Endowed Chair Professor of Biochemistry, Biophysics and Structural Biology Susan Marqusee has been honored as a fellow in The Biophysical Society.
The Biophysical Society has honored Susan Marqusee as a 2015 Society Fellow for her work as one of the world’s top experimentalists in the field of protein folding, which has had, and continues to have, a significant impact in the field of protein biophysics in general.
While working as a Professor in MCB's Division of Immunology, Dr. Jim Allison developed the immunotherapy drug Yervoy (Ipilimumab), the first drug to improve overall survival for patients with advanced metastatic melanoma, the deadliest form of skin cancer. Yervoy was an informative feature story for the Association of University Technology Managers (AUTM) that describes both the research and the technology transfer process.